DAWEX
Dawex , the leading technology company for data exchange, data marketplace and data hub, unveils the MGTS Data Marketplace, the first non-personal data marketplace for the automotive sector (distribution, sales, use, wear and tear, maintenance and equipment), and more globally for individual mobility. The MGTS Data Marketplace aims at bringing together all stakeholders and observers of today's and tomorrow's individual mobility to enable its users to understand, anticipate and innovate in this rapidly changing sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505006017/en/
Present in 18 countries with 2,000 customer contact points under the Midas, Norauto and ATU multi-brand car maintenance banners, Mobivia is the leader in its sector with over 50 million customers per year and 50 years of existence.
"Dawex provided us with the technology solution to monetize and generate value from our data or those of our partners, by creating a Data Exchange Platform that is powerful, efficient, secure and easy to use," explains Ludovic Codeluppi, International Product Leader at MGTS.
The MGTS Data Marketplace leverages Dawex Data Exchange technology to facilitate the collection, centralization, distribution, exchange and monetization of non-personal data in this sector. The different market players keep control over their data, decide with whom to share it and for what purposes, in an environment that guarantees security and traceability. Thanks to Dawex business and regulatory expertise, the MGTS Data Marketplace meets the requirements of European and international regulations, and is perfectly in line with the future Data Act .
"In less than a year, MGTS has built strong relationships with organizations outside of our immediate ecosystem thanks to Dawex introductions," continues Ludovic Codeluppi. "The circulation and commercialization of data between these stakeholders will play a key role in the development of new business models.”
Dawex technology enables MGTS to orchestrate and animate a vast data ecosystem from the automotive and mobility sector. It provides its stakeholders with the means to better understand and improve their user experience, increase productivity and efficiency, and boost innovation. The MGTS deployment is another illustration of Dawex technology leadership, demonstrating the footprint of its solid reference architecture.
"Data exchange has become a fundamental component of business competitiveness and economic sovereignty," comments Fabrice Tocco, Dawex co-CEO. "Organizing the circulation and monetization of its data within its ecosystem is an imperative for all players in the retail sector.”
Sign up to the MGTS Data Marketplace
About Dawex
In today’s economy where data has become a product of unlimited potential, with its own value, and a source of new revenue streams, Dawex technology allows organizations to create new ecosystems around data exchange platforms that meet regulatory requirements and address traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub to orchestrate the sourcing, the distribution and the exchange of data. Awarded Technology Pioneer by the World Economic Forum in 2020, Dawex is an active member of Gaia-X . Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505006017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
